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Context: Inactivating germline mutations in the aryl hydrocarbon receptor interacting protein (AIP)
gene are linked to pituitary adenoma predisposition. Here, we present the youngest known patient
with AIP-related pituitary adenoma.
Case Description: The patient presented at the age of 4 years with pituitary apoplexy and left ptosis
with severe visual loss following a 1-year history of abdominal pain, headaches, and rapid growth. His
IGF-1 level was 53 the upper limit of normal, and his randomGH level was 1200 ng/mL. MRI showed a
433 243 35‒mmadenomawith suprasellar extension invading the left cavernous sinus (Knosp grade
4). After transsphenoidal surgery, histology showedagrade2A sparsely granulated somatotropinoma
with negative O6-methylguanine-DNA methyltransferase and positive vascular endothelial growth
factor staining. Genetic testing identified a heterozygous germline nonsense AIP mutation
(p.Arg81Ter). Exome sequencing of the tumor revealed that it had lost the entire maternal
chromosome-11, rendering it hemizygous for chromosome-11 and therefore lacking functional
copies of AIP in the tumor. He was started on octreotide, but because the tumor rapidly regrew
and IGF-1 levels were unchanged, temozolomidewas initiated, and intensity-modulated radiotherapy
was administered 5 months after surgery. Two months later, bevacizumab was added, resulting in
excellent tumor response. Although these treatments stabilized tumor growth over 4 years, IGF-1 was
normalized only after pegvisomant treatment, although access to this medication was intermittent. At
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3.5 years of follow-up, gamma knife treatment was administered, and pegvisomant dose increase was
indicated.
Conclusion: Multimodal treatment with surgery, long-acting octreotide, radiotherapy, temozolomide,
bevacizumab, and pegvisomant can control genetically driven, aggressive, childhood-onset
somatotropinomas. (J Clin Endocrinol Metab 104: 3539–3544, 2019)
Screening for genetic alterations is recommended inpatients with childhood-onset pituitary adenomas
even with no apparent family history (1, 2). Here, we
report on a 4-year-old child who presented with an
aggressive somatotropinoma harboring a heterozy-
gous aryl hydrocarbon receptor interacting protein
(AIP) mutation and who, in addition to surgery and
radiotherapy, required a somatostatin analogue, peg-
visomant, temozolomide, and bevacizumab therapy to
control tumor growth and hormone excess. Written
informed consent was obtained from the parents of the
patient for publication of this case report and associ-
ated images.
Case Presentation
A 4-year-old boy presented to the neurosurgical de-
partment with intense headaches, vomiting, ptosis, and
only light perception in the left eye following a 12-month
history of abdominal pain and headaches. Acanthosis
nigricans, multiple cafe´-au-lait spots, excessive sweat-
ing, and dental malocclusion were noted. A clinical
diagnosis of pituitary apoplexy was made. He had
tall stature [height 12.5 SD score (SDS); midparental
height 10.3 SDS] developing over the previous year
(growth velocity, 12.8 cm/y; 50th percentile 5 7 cm/y).
The child was irritable, aggressive, and hyperkinetic with
poor attention span. His serum IGF-1 level was 53 the
upper limit of normal (ULN) and his GH level was
1200 ng/mL, whereas his prolactin, free T4, TSH, 9 AM
cortisol, hemoglobin A1c, calcium, and electrolyte levels
were within the normal range. MRI showed a 433 243
35‒mm tumor with suprasellar and left cavernous ex-
tension (Knosp grade 4) and evidence of acute bleeding in
the tumor (Fig. 1A). Craniospinal MRI, whole body
gallium-68 DOTATATE scan, and cerebrospinal fluid
examination for tumor cells excluded systemic dissemi-
nation of the disease. There was no known family history
of pituitary adenoma or gigantism (Fig. 1F), and family
members were well. His paternal grandfather had
a history of hyperparathyroidism due to a parathy-
roid adenoma. Genetic analysis revealed a previously
repeatedly described (3–6) germline nonsense AIP mu-
tation (c.241C.T; p.Arg81Ter) (Fig. 1G) in the pro-
band and three family members with normal clinical,
biochemical, and MRI assessments. Whole-exome
sequencing on peripheral and tumor DNA revealed
that 1293 variants of the 1311 detected heterozy-
gous germline chromosome 11 variants were hemizy-
gous (suggesting loss of heterozygosity) in tumor DNA,
strongly suggesting loss of the entire maternal chromo-
some 11 (Fig. 1G and 1H). Somatic mutations in the
tumor were analyzed using VarScan (v2.6.x) andMuTect
(v1.1.4), whereas germline sequence variations were
called using GATK’s UnifiedGenotyper. The effect of
variants on protein function was predicted using SIFT
and PolyPhen2 scores, and annotation was performed
using ANNOVAR (release: March 2015) and SnpEff
(v4.1). OMIM, ClinVar, and COSMIC databases were
used for annotation of identified variants. Minor allele
frequencies were obtained from the dbSNP (build 142),
1000 Genomes, and ExAC databases.
Treatment
The patient underwent transsphenoidal surgery after
diagnosis. Histopathology showed a sparsely granulated
somatotropinoma with areas of hemorrhage, suggestive
of recent apoplexy. The Ki-67 index was 12%, with
negative p53, moderately positive vascular endothelial
growth factor (VEGF) staining, negative O6-methyl-
guanine-DNA methyltransferase (MGMT) immuno-
staining, and methylation of the MGMT promoter by
PCR. The tumor could be classified as grade 2A
(Trouillas classification). Immediate postoperative MRI
showed a large left parasellar remnant. Octreotide-long-
acting release (LAR) was implemented (20 mg per
month) without effect on IGF-1 levels (Fig. 2). One
month after surgery, there was a substantial increase in
the size of the parasellar tumor remnant (Fig. 1B);
therefore, the patient was started on temozolomide
(180 mg/d, 5 d/mo) (Fig. 2). Four months after surgery,
fractionated intensity-modulated radiotherapy (40 Gy; 23
sessions) was given to the left cavernous sinus remnant
and IV anti-VEGF bevacizumab was initiated (first cycle:
5mg/kg; second to fifth cycles: twoweekly cycles, 7.5mg/kg;
from cycle 6 onward: 10 mg/kg). Postoperative MRIs at
3- to 6-month intervals showed a steady reduction in
tumor size (Fig. 1C).
By the sixth postoperative month, his left ptosis had
resolved, but there was no improvement in the visual
acuity of the left eye. Serum GH (.50 ng/mL) and IGF-1
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(33 ULN) levels remained high, whereas the tumor
showed significant shrinkage. One year after surgery,
pegvisomant was added at the dose of 10 mg/d, and IGF-1
fell to a normal level (0.63ULN).Octreotidewas stopped,
but temozolomide and bevacizumab were continued. The
patient’s IGF-1 level remained in the normal range for the
following 2 months. For financial reasons, the pegvi-
somant supply was unreliable, and the drug dose had
to be first reduced and then stopped; however, it was
later intermittently reinstated (Fig. 2). When pegvisomant
was administered, the IGF-1 level rapidly dropped and
remained stable, whereas it was elevated when pegvi-
somant was not administered (Fig. 2).
Four years after surgery, both temozolomide (38
months of treatment) and bevacizumab (35 months
of treatment) were stopped because no further tumor
shrinkage was seen, to reduce toxicity, and given that
pubertal induction would be initiated soon and temo-
zolomide is an alkylating agent with potential gonadal
toxicity. Octreotide-LAR (20 mg/mo) and pegvisom-
ant (10 mg/d) were restarted, as there are data sug-
gesting synergism between these two medications (8).
After a multidisciplinary team discussion and con-
sidering the persistently uncontrolled GH excess at
42 months after surgery, gamma knife radiotherapy
was administered to the tumor remnant (13 Gy at
50%) (Fig. 1D).
The patient’s current height is 145 cm (99.5th per-
centile; SDS 12.58). The latest MRI showed a stable
tumor remnant with some necrosis (Fig. 1E). The patient
is receiving T4 and hydrocortisone replacement, and
pubertal initiation is planned in a few years; careful
timing of this may help to optimize final height. Current
treatment includes monthly 20-mg octreotide-LAR and
daily 10-mg pegvisomant, with IGF-1 ranging from 1.23
to 1.43 ULN. Because of the high growth velocity and
suboptimal IGF-1 control, pegvisomant dose increase is
indicated.
Figure 1. Coronal T1-weighted MRI of the sella showing a large pituitary adenoma with left cavernous sinus invasion (A) at diagnosis; (B) 1
month after surgery; (C) 16 months after surgery; (D) 42 months after surgery, just before gamma knife therapy; and (E) 52 months after
surgery, 9 months after gamma knife therapy. (F) The family pedigree chart shows incomplete penetrance. The arrow marks the proband. (G)
Sanger sequencing shows a heterozygous AIP c.241C.T mutation in blood leukocytes and loss of heterozygosity in the tumor. (H) Genomic
positions with loss of heterozygosity in the tumor sample were identified using VarScan and are marked in blue.
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Discussion
AIP mutation‒positive somatotropinomas are often ag-
gressive and treatment resistant, and the onset of first
symptoms typically occurs in the second decade of life.
This patient, who already had increased growth rate from
the age of 3 years, is the youngest known patient with an
AIPmutation‒positive pituitary somatotropinoma. He is
also the first pediatric patient with a pituitary adenoma
treated with bevacizumab and the first patient with AIP
mutation positivity treated with the combination of
temozolomide and bevacizumab. The combination of
surgery, radiotherapy, octreotide, temozolomide, and
bevacizumab controlled his tumor growth, whereas bio-
chemical control was achieved only when pegvisomant
was added.
There is now considerable experience with temozo-
lomide in pituitary adenomas in adults (9). Four pediatric
patients treated with temozolomide for a pituitary tumor
(10–12) were previously described, whereas reports of
two more patients with childhood-onset disease and
temozolomide treatment in adulthood (13, 14) were
published. Temozolomide was initiated in the current
case because of aggressive tumor behavior showing rapid
enlargement after surgery, with the aim of controlling
tumor growth and sensitizing it to radiotherapy (15).
Bevacizumab was considered because of positive VEGF
immunostaining in the tumor and in view of previous
successful use in a patient with a pituitary carcinoma that
resulted in prolonged (.8 years) control of tumor growth
and survival [(16) and personal communication with Dr
Luis Syro,Medellin, Colombia]. VEGF staining is present
in somatotroph adenomas, and we have not seen a
difference between AIP mutation‒positive and AIP
mutation‒negative cases (17). Both treatments were
started with the hope of achieving additive or augmented
effects, as data from patients with glioblastoma multi-
forme showed the combination of these two drugs
causing remarkable tumor reduction along with sur-
vival benefits [(18) and ClinicalTrials.gov Identifier:
NCT00612339, phase II, 2008]. Recently, temozolomide
and bevacizumab treatment was stopped, as no further
benefit was seen.
Our patient was 3 years old at the time of his first
symptoms. Because of the presence of cafe´-au-lait spots,
age ,5 years at onset, and apparent sporadic pre-
sentation, McCune-Albright syndrome and X-linked
acrogigantism were considered as differential diagnoses.
Technetium-99m methylene diphosphonate bone scan
and genetic analysis of the tumor tissue ruled out
McCune-Albright syndrome. X-linked acrogigantism due
toGPR101 duplication was ruled out with droplet digital
PCR analysis (19). MEN1 syndrome was considered
because of the paternal grandfather’s parathyroid
disease; however, his age at onset of hyperparathy-
roidism was quite late, and no other MEN1-related
Figure 2. IGF-1 and height velocity during multimodal therapy. IGF-1 is expressed as times ULN (3ULN). The dotted green line represents the
ULN for IGF-1, and the dashed purple line represents the 50th percentile height velocity for ethnically matched boys (7). IMRT, fractionated
intensity-modulated radiotherapy; TSS, transsphenoidal surgery.
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manifestations were present in the family. In addition,
childhood-onset somatotropinomas are extremely rare
in the setting of MEN1 syndrome, in which pediatric
GH excess is more likely to arise from GHRH-secreting
neuroendocrine tumors. Exome sequencing did not iden-
tify pathogenic variants in the MEN1 gene. The patient
was investigated for possible metastatic disease. Al-
though pituitary carcinomas have not been reported in
patients with AIP mutations, they have been observed in
other genetic pituitary adenoma predisposition syn-
dromes [MEN1 (20, 21), SDHB (22), AIP mutation‒
negative familial isolated pituitary adenoma (23, 24)]
and in one patient with Lynch syndrome (25). A literature
search identified three cases of pituitary carcinomas
in patients with childhood-onset pituitary tumors,
although none of them were somatotropinomas (13,
26, 27).
Apoplexy has been associated with AIP mutation‒
positive tumors (6, 28); currently, it is unclear whether
the rapid tumor growth, the younger age, or a specific
AIP-related molecular mechanism is responsible for this
observation. The apparent sporadic presentation of our
patient highlights the low penetrance seen among AIP
mutation carriers. Loss of the entire maternal (wild-type)
copy of chromosome 11 may play a role in his partic-
ularly early and aggressive manifestation. The patient
showed fluctuations in his growth patterns. Some could
be explained by changes in IGF-1 levels, but not all. There
was a deceleration in height velocity during the first
6 months after surgery, followed by acceleration again.
He also showed rapid growth after temporary cessation
of pegvisomant. Growth can be a periodic phenomenon
influenced by many factors, including intermittent chon-
drocyte recruitment and senescence. This programmed
senescence does not appear to be caused by hormonal or
other systemic mechanisms but is intrinsic to the growth
plate itself (7, 29).
In conclusion, patients with somatotropinomas
often require multimodal treatment. Although we
were able to control aggressive tumor growth with
surgery, radiotherapy, temozolomide, bevacizumab,
and octreotide-LAR in this patient, excess hormone
release was curbed only by pegvisomant. The appli-
cation of an extensive armamentarium of interventions
can control aggressive disease, although costs can be
prohibitive even in developed countries, let alone in
low-income states.
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